Carvedilol Tablet, Film Coated
Product Images NDC 63187-946

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 63187-946). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A line graph titled "Survival Analysis for COPERNICUS (Intent-to-Treat)" depicting percent mortality over 21 months. The graph compares two curves labeled "Placebo" and "Carvedilol," with mortality on the y-axis and time in months on the x-axis. A p-value of 0.004 is noted on the graph.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot titled 'Effects on Mortality for Subgroups in COPERNICUS' showing hazard ratios for different patient subgroups, including demographics (men, women, age groups, race), medical conditions (diabetic status, ischemic status), heart rate, systolic blood pressure, and spironolactone use. Each subgroup has a horizontal line with a dot representing the hazard ratio and confidence intervals, plotted against a horizontal axis ranging from 0.0 to 2.0 hazard ratio, with a vertical dashed line at 1.0 representing the reference line.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A line graph titled 'Survival Analysis for CAPRICORN (Intent-to-Treat)' showing percent mortality over a 24-month period. The graph compares two groups: one treated with Carvedilol and the other with a placebo. The Y-axis represents percent mortality (0 to 30%), and the X-axis shows time in months (0 to 24). The Carvedilol line remains below the placebo line, indicating lower mortality, with a significance value of P = 0.03.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A figure titled 'Effects on Mortality for Subgroups in CAPRICORN' showing two forest plots of hazard ratios with confidence intervals for various patient subgroups. Subgroups include age, gender, timing post-MI, prior IV/oral beta-blocker use, Killip class, thrombolytic therapy, PTCA for MI, current/prior CHF, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure, accompanied by hazard ratio values and horizontal lines representing confidence intervals.*

FDA Label Image

63187-946-60 (Carvedilol Fig6)

Carvedilol 6.25 mg film-coated tablets label by Proficient Rx LP. The label states the package contains 60 tablets, each containing 6.25 mg of Carvedilol USP. Tablets are white to off-white, oval-shaped, and debossed with 'E' on one side and '02' on the other. Manufactured by Aurobindo Pharma Limited Hyderabad, India.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure diagram of carvedilol showing its molecular arrangement with functional groups and bonds. The structure includes an indole-like core and ether linkages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.